Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Allogeneic Stem Cell Transplantation for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion - NYMC 588

NCT04099966 is registered in ClinicalTrials.gov with Mitchell Cairo as lead sponsor.

NCT NCT04099966
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04099966 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Allogeneic Stem Cell Transplantation for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion - NYMC 588
Lead sponsor
Mitchell Cairo
Phase
Phase 2
Overall status
Recruiting
Start date
April 1, 2021
Completion date
December 31, 2027
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute leukemia, amegakaryocytic thrombocytopenia, beta-thalassemia, diamond blackfan anemia, hodgkin lymphoma, kostmann, non-hodgkin lymphoma, severe aplastic anemia, sickle cell disease